Virology

TESTD Announces Software Platform For COVID-19 Medical Tests, Test Management Tools, And Vaccine Verification

Tuesday, March 2, 2021 - 3:37pm

Hilton Hotel signs with TESTD for weekly employee COVID test scheduling and monitoring on blockchain secured platform.

Key Points: 
  • Hilton Hotel signs with TESTD for weekly employee COVID test scheduling and monitoring on blockchain secured platform.
  • TESTD platform tracks vaccine status, too
    Developed as a result of the COVID-19 pandemic and the demand it created for broad testing and test management, the TESTD platform also verifies vaccinations, displaying one badge after a single-dose vaccine has been administered, and two badges for a two-dose vaccine.
  • Digital vaccine verification on the TESTD platform provides a safe alternative to vaccine cards, which can be lost, damaged, or counterfeited.
  • TESTD's initial product is its platform TESTD, which automates medical test scheduling, manages testing data, and organizes the data for easy reporting.

ShiftMed Survey Shows 65.5% of Nursing Staff Want the Vaccine

Tuesday, March 2, 2021 - 1:33pm

A downloadable summary report on the ShiftMed website reveals how nursing staff, mostly RN, LPN, or CNAs, feel about the vaccine and why some are reluctant to get vaccinated.

Key Points: 
  • A downloadable summary report on the ShiftMed website reveals how nursing staff, mostly RN, LPN, or CNAs, feel about the vaccine and why some are reluctant to get vaccinated.
  • To save lives, protect themselves and their families, health care workers should get the vaccine.
  • Interesting statistics from the survey include:
    Seventy-five percent of the survey participants have not had the vaccine, while 25% have.
  • Staff will not get the vaccine because many feel the vaccine was developed too quickly, might be unsafe, or have too many immediate side effects.

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Tuesday, March 2, 2021 - 1:07pm

Under the agreement, Aegea will supply the COVID-19 assay kit to Biocept for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory developed test (LDT).

Key Points: 
  • Under the agreement, Aegea will supply the COVID-19 assay kit to Biocept for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory developed test (LDT).
  • The new COVID-19 assay is a next-generation PCR-based test using proprietary Switch-Blocker technology for viral RNA detection as well as discrimination of L- and S-strain types.
  • The assay may have the ability to evaluate sample adequacy in patients with negative results and be adapted to identify new variants of the SARS-CoV-2 virus as they emerge.
  • A key priority will be quantifying viral load to determine how patients are responding to therapy and better assess how infectious they may be.

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Tuesday, March 2, 2021 - 1:07pm

Under the agreement, Aegea will supply the COVID-19 assay kit to Biocept for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory developed test (LDT).

Key Points: 
  • Under the agreement, Aegea will supply the COVID-19 assay kit to Biocept for validation in its CLIA-certified, CAP-accredited high-complexity molecular lab and subsequent commercialization of a laboratory developed test (LDT).
  • The new COVID-19 assay is a next-generation PCR-based test using proprietary Switch-Blocker technology for viral RNA detection as well as discrimination of L- and S-strain types.
  • The assay may have the ability to evaluate sample adequacy in patients with negative results and be adapted to identify new variants of the SARS-CoV-2 virus as they emerge.
  • "A key priority will be quantifying viral load to determine how patients are responding to therapy and better assess how infectious they may be.

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Tuesday, March 2, 2021 - 12:30pm

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points: 
  • The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
  • The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
  • Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
  • Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

"Corona Virus Vaccine Market Size is Projected to reach 75.75 Billion by end of 2021, Says Brandessence Market Research"

Tuesday, March 2, 2021 - 12:30pm

The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.

Key Points: 
  • The global corona virus vaccine market is expected to grow at significant growth rate due to number of driving factors.
  • The study provides a crucial view of global corona virus vaccine market by segmenting the market based on infection type, vaccine type and region & country level.
  • Based on infection, the corona virus vaccine market is segmented into HCoV-229E, HCoV-OC43, HKU1-CoV, NL63, MERS-CoV, New Haven CoV, SARS-CoV and SARS-CoV-2.
  • Based on vaccine type, the market is segmented into S-protein based coronavirus vaccine, live attenuated coronavirus vaccine, inactivated coronavirus vaccine, MRNA vaccine and DNA-based vaccine.

Penn Wharton Budget Model Projects 3 Million COVID-19 Vaccinations Per Day Would Add 2 Million Jobs, Increase Real GDP By 1 Percent

Monday, March 1, 2021 - 8:20pm

Doubling the number of vaccine doses administered daily to 3 million per day would boost employment by adding 2 million jobs and increase real GDP by about 1 percent over the summer, with smaller effects later in the year.

Key Points: 
  • Doubling the number of vaccine doses administered daily to 3 million per day would boost employment by adding 2 million jobs and increase real GDP by about 1 percent over the summer, with smaller effects later in the year.
  • However, doubling the pace of vaccinations to 3 million per day would prevent a total of about 2 million cases in 2021.
  • Each year 13,000 professionals from around the world advance their careers through Wharton Executive Education's individual, company-customized, and online programs.
  • More than 99,000 Wharton alumni form a powerful global network of leaders who transform business every day.

World Vaccine Storage & Packaging Market Report 2020-2027: Catalent/Moderna Partnership for Vial Filling & Packaging Capacity

Monday, March 1, 2021 - 8:00pm

The global vaccine storage & packaging market size is expected to reach USD 43.8 billion by 2027, according to the study.

Key Points: 
  • The global vaccine storage & packaging market size is expected to reach USD 43.8 billion by 2027, according to the study.
  • Vaccine storage equipment is the laboratory equipment utilized to maintain and preserve the life of vaccines in the desired condition.
  • Vaccine storage equipment provides storage at varying temperatures ranging from 86 to 65 degree Celsius.
  • However, technological developments in refrigerators and freezers utilized for vaccine storage and transportation will further fuel the market growth.

India $2.3 Billion COVID-19 Vaccines Market to 2027: Approval/Launches of New Vaccines / Rising Focus on Immunization Programs / Increasing Government Support for Vaccine Development

Monday, March 1, 2021 - 7:45pm

India's COVID-19 vaccines market is anticipated to grow over US$ 2.3 Billion by 2027 with an impressive CAGR of more than 25% during the forecast period.

Key Points: 
  • India's COVID-19 vaccines market is anticipated to grow over US$ 2.3 Billion by 2027 with an impressive CAGR of more than 25% during the forecast period.
  • The report offers the most up-to-date industry data on the actual market situation and future outlook for the India COVID-19 vaccines market.
  • The report also delivers a detailed assessment of the latest happenings in the Indian COVID-19 vaccines market.
  • The report concludes with the profiles of the key players in the Indian COVID-19 vaccines market.

Do You Want a Long and Healthy Life? Take Care of the latent Viruses Hiding in Your Body -- CBCD Reports Publication of a New Study

Monday, March 1, 2021 - 3:19pm

This means that the virus does not cause any easy to recognize symptoms, such as fever, weakness, headache, pain, etc.

Key Points: 
  • This means that the virus does not cause any easy to recognize symptoms, such as fever, weakness, headache, pain, etc.
  • Recently, Dr. Hanan Polansky and his team published many studies showing how latent viruses cause major diseases.
  • (2) Polansky H, Lori G. How microcompetition with latent viruses can cause synuclein aggregation, mitochondrial dysfunction, and eventually Parkinson's disease.
  • Drug Design, Development and Therapy 2016:10 2713-2722
    (8) Polansky H, Itzkovitz E. Gene-Eden-VIR is antiviral: results of a post marketing clinical study.